Company: SCLXW
Filing Date: 2025-12-29
Form Type: 424B3
Source: 0001193125-25-335429
Chunk: 78

Company: Scilex Holding Co
Filing Date: 2025-12-29
Form: 424B3
Chunk 78
---
 prior U.S. government international trade policy and has commenced activities to renegotiate, or potentially terminate, certain existing bilateral or multi-lateral trade agreements and treaties with foreign countries. In addition, the new administration has initiated or is considering imposing tariffs on certain foreign goods. Related to this action, certain foreign governments, including China, have instituted or are considering imposing tariffs on certain U.S. goods. It remains unclear what the new administration or foreign governments will or will not do with respect to tariffs or other international trade agreements and policies. Although the new administration has not yet implemented tariffs on pharmaceuticals, there can be no assurance that it will not implement such tariffs in the future. A trade war or other governmental action related to tariffs or international trade agreements or policies has the potential to disrupt our research activities, affect our suppliers, increase the cost of materials purchased to manufacture our products, impact our ability to sell our products outside the United States or to sell our products outside the United States at competitive prices and/or to affect the United States or global economy or certain sectors thereof and, thus, could adversely impact our business. Conducting business internationally involves a number of risks, including:

| • |     | multiple, sometimes conflicting and changing laws and regulations such as tax laws, export and import                                                 
 restrictions, employment laws, anti-bribery and anti-corruption laws, regulatory requirements and other governmental approvals, permits and licenses; |

| • |     | difficulties in enforcing our intellectual property rights and in defending against third-party threats and 
 intellectual property enforcement actions against us, our distributors or any of our third-party suppliers; |

| • |     | failure by us or our distributors to obtain appropriate licenses or regulatory approvals for the sale or use of 
 our product candidates, if approved, in various countries;                                                      |

| • |     | difficulties in managing foreign operations; |

50

| • |     | cost and availability of shipping and other means of product transportation; |

| • |     | foreign currency exchange rate fluctuations; |

| • |     | changes in duties and tariffs, license obligations and other non-tariff 
 barriers to trade;                                                      |

| • |     | the imposition of new trade restrictions; |

| • |     | difficulties in enforcing agreements and collecting receivables through certain foreign legal systems; |

| • |     | complexities associated with managing multiple payor-reimbursement regimes or 
 self-pay systems;                                                             |

| • |     | natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak